- Poster presentation
- Open Access
Effects of mild therapeutic hypothermia on acute kidney injury after cardiopulmonary resuscitation
© Hasslacher et al.; 2015
- Published: 1 October 2015
- Renal Replacement Therapy
- Acute Kidney Injury
- Neurological Outcome
- Continuous Renal Replacement Therapy
About the effect of mild therapeutic hypothermia on renal function after cardiopulmonary resuscitation little data exists. From animal and human studies it is known that renal function might be impaired, which is not reflected by serum creatinine levels if creatinine production is reduced.
The aim of the study was to investigate the possible influence of mild therapeutic hypothermia (MTH) on the incidence of acute kidney injury (AKI) and renal function parameters [].
This is a retrospective analysis of prospectively collected data on patients after successful cardiopulmonary resuscitation (CPR) at our ICU. Serum creatinine and cystatin C were measured at baseline, daily up to 5 days and at ICU discharge. AKI was defined by the KDIGO criteria (only based on creatinine values). MTH was applied for 24 hours targeting a temperature of 33°C using an intravascular cooling device. Neurological outcome was assessed with the Cerebral Performance Categories (CPC) score at hospital discharge.
55 of 126 patients were treated with MTH, 20 patients received continuous renal replacement therapy, 62 of 126 patients had good neurological outcome (CPC 1-2). In patients treated with MTH there was a significantly lower incidence of AKI (9 vs 20; p = 0.007) accompanied by significantly lower creatinine levels on day 1-2 and at ICU discharge (day 1: 1.12 (0.90-1.29) vs. 1.29 (1.00-1.52) mg/dl; p= 0.016) and lower cystatin C levels on day 1-4 and ICU discharge (day 1: 0.88 (0.77-1.10) vs. 1.29 (1.06-2.16)mg/l; p < 0.001). Restricting analysis to patients with good neurological outcome confirmed a significant lower creatinine on day 2 (0.82 (0.67-1.02) vs. 1.03 (0.83-1.38) mg/dl; p = 0.049) and cystatin C on day 1-2 when treated with MTH. In patients with poor neurological outcome treated with MTH cystatin C levels were also significantly lower on day 1-2 (day 1: 0.96 (0.83-1.30) vs. 1.44 (1.17- 2.29) mg/l; p = 0.01) and at ICU discharge, whereas creatinine was only significantly lower at ICU discharge (0.84 (0.51-1.36) vs. 1.23 (0.87-2.15) mg/dl; p = 0.039). AKI occurred significantly less often (10 vs. 35; p = 0.017) in this subgroup.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.